Everyone in the obesity-medicine world has been waiting for the same trial. For three years, cross-trial comparisons told the same story: tirzepatide (Zepbound) seemed to drive more weight loss than semaglutide (Wegovy). But cross-trial inference is a weak argument — patient populations, titration schedules, and definitions of response all differ. In 2025, Eli Lilly finally reported SURMOUNT-5, the first randomised head-to-head Phase 3 trial of the two drugs. The result was decisive, and it has already begun to redraw the obesity treatment landscape heading into 2026.
Key Takeaways
- Direct head-to-head. SURMOUNT-5 is the first randomised Phase 3 trial comparing maximum-tolerated-dose tirzepatide (up to 15 mg) against maximum-tolerated-dose semaglutide (up to 2.4 mg) in obesity.
- 20.2% vs 13.7% weight loss at 72 weeks (tirzepatide vs semaglutide) — a 47% relative advantage for tirzepatide.
- 31.6% of tirzepatide patients lost ≥25% of body weight vs 16.1% on semaglutide.
- Waist circumference reductions were substantially greater on tirzepatide (-18.4 cm vs -13.0 cm).
- GI tolerability was similar. Both arms had comparable rates of nausea, diarrhea, and discontinuation — the magnitude advantage was not paid for in side effects.
- Published in NEJM (2025). SURMOUNT-5 was the clean experiment the field had been missing. It settles cross-trial debate on efficacy, though access, cost, and tolerability still shape real-world choice.
Why SURMOUNT-5 Had to Happen
The dominant mental model in obesity medicine from 2022 to 2024 was built on indirect comparisons. STEP-1 showed semaglutide 2.4 mg produced ~15% weight loss at 68 weeks. SURMOUNT-1 showed tirzepatide 15 mg produced ~22% weight loss at 72 weeks. Clinicians inferred tirzepatide was more effective — but STEP-1 and SURMOUNT-1 enrolled different patients and used different titration schemes. Payers, formulary committees, and skeptical endocrinologists kept asking for direct evidence.
SURMOUNT-5 was designed to answer the question with no ambiguity: same inclusion criteria, same titration cadence, same follow-up window, randomised 1:1. The question was simply: when you can pick either, which drug wins on efficacy?
Trial Design
The study enrolled 751 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity — but without type 2 diabetes. Participants were randomised 1:1 to:
- Tirzepatide subcutaneous once weekly, titrated to the maximum tolerated dose of 10 mg or 15 mg
- Semaglutide subcutaneous once weekly, titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg
Both arms used the manufacturer-recommended escalation schedules — tirzepatide every 4 weeks from 2.5 mg, semaglutide every 4 weeks from 0.25 mg. Primary endpoint: percent change in body weight at week 72. Key secondary endpoints: proportion achieving ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% weight loss.
The Headline Results
At week 72:
- Tirzepatide: –20.2% body weight
- Semaglutide: –13.7% body weight
- Treatment difference: –6.5 percentage points in favour of tirzepatide (highly statistically significant)
Translating to absolute pounds for a 220 lb starting weight: tirzepatide patients lost ~44 lb on average; semaglutide patients lost ~30 lb. On every pre-specified threshold, tirzepatide had more responders:
- ≥5% loss: 94.3% vs 85.6%
- ≥10% loss: 81.6% vs 60.5%
- ≥15% loss: 64.5% vs 40.1%
- ≥20% loss: 48.4% vs 27.3%
- ≥25% loss: 31.6% vs 16.1%
The ≥25% response rate roughly doubled with tirzepatide. That matters — ≥20% weight loss is the threshold where comorbidity reversal (type 2 diabetes remission, OSA improvement, blood pressure normalisation) starts to show up robustly in observational cohorts.
Why the Mechanism Matters
Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide is a dual agonist of GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) was historically considered unhelpful for weight loss in isolation, but in combination with GLP-1 agonism it appears to enhance adipose-tissue insulin sensitivity, modulate energy expenditure, and blunt some of the GI side effects that otherwise cap GLP-1 dosing.
SURMOUNT-5 is best read as empirical validation of the GLP-1/GIP combination hypothesis. The incremental 6.5 percentage points at the top dose is roughly what retatrutide's triple-agonism theory predicts the next step up should look like (retatrutide adds glucagon receptor agonism and hits ~24–28% at 48 weeks).
Safety and Tolerability
One of the most important findings of SURMOUNT-5 was that the efficacy gap did not come at a tolerability cost:
- GI adverse events (nausea, diarrhea, constipation, vomiting) occurred at similar rates in both arms
- Treatment discontinuation due to adverse events was comparable
- Serious adverse events were low and balanced between arms
- No new safety signals specific to the head-to-head comparison emerged
This tracks with the hypothesis that GIP co-agonism blunts some of the GI penalty of pure GLP-1 escalation. In practical terms: patients on tirzepatide got more weight loss per unit of nausea.
What SURMOUNT-5 Does Not Settle
It would be easy to read SURMOUNT-5 as "tirzepatide wins, prescribe accordingly." That overreads the trial. Several questions remain:
- Cardiovascular outcomes. Semaglutide has a positive CV outcomes trial (SELECT). Tirzepatide's SURPASS-CVOT and SURMOUNT-MMO are still reading out. Until then, semaglutide retains the CV-prevention edge.
- Diabetes populations. SURMOUNT-5 enrolled non-diabetic obesity. In type 2 diabetes, the gap may be narrower.
- Cost and access. Both drugs are expensive and insurance-dependent. In practice, the choice is often "which one the payer approves," not "which is more effective."
- Durability. 72 weeks is a snapshot. Longer-term weight-regain patterns on discontinuation (seen in STEP-5 and SURMOUNT-4 extensions) still matter.
How This Reshapes 2026
Three implications are already visible:
- Tirzepatide becomes the default first-line injectable for obesity in payer formularies that cover both.
- Semaglutide retains a distinct lane — CV-outcome prevention, type 2 diabetes with established cardiovascular disease, and markets where tirzepatide is unavailable or restricted.
- The retatrutide bar moves up. If retatrutide can meaningfully exceed 20% in Phase 3 (and TRIUMPH-1 interim suggests it can), it becomes the obvious successor target.
Frequently Asked Questions
Does SURMOUNT-5 mean tirzepatide is "better" than semaglutide?
For weight loss magnitude in non-diabetic obesity: yes, decisively. For cardiovascular prevention, semaglutide still has the stronger evidence base (SELECT trial). "Better" depends on the clinical goal.
Were the semaglutide patients titrated correctly?
Yes. The trial used the manufacturer-labelled escalation schedule, reaching 2.4 mg (the approved maximum obesity dose) in patients who tolerated it. This was not a stacked-deck comparison.
Why was semaglutide 2.4 mg used instead of a higher experimental dose?
Because 2.4 mg is the approved and marketed dose for obesity. Higher doses (e.g. 7.2 mg) are being studied but are not labelled, so a head-to-head would not be comparing clinically available options.
What does SURMOUNT-5 mean for patients already on semaglutide?
Patients doing well on semaglutide and tolerating it should not switch reflexively. But patients whose weight loss has plateaued short of their goal may discuss switching to tirzepatide with their clinician — expected incremental loss would be meaningful.
How does this compare to oral GLP-1s like orforglipron?
Orforglipron (oral small-molecule GLP-1) produced ~12.4% in ATTAIN-1. Pure GLP-1 oral < pure GLP-1 injectable < GLP-1/GIP injectable. SURMOUNT-5 confirms that ordering.
Does SURMOUNT-5 affect compounded tirzepatide and semaglutide?
Not directly — the trial used branded product. But it may increase demand pressure for tirzepatide specifically, which has implications for both brand supply and the regulatory status of compounded versions. See our prior coverage of the FDA 503B bulks list for the compounding backdrop.
Primary sources:
- New England Journal of Medicine — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
- Eli Lilly Investor Release — SURMOUNT-5 topline results
- ClinicalTrials.gov — NCT05822830 SURMOUNT-5 protocol
Research disclaimer: This article summarises published Phase 3 trial data for educational purposes. It does not constitute medical advice. Decisions about GLP-1 therapy should be made with a licensed clinician who can account for individual medical history, cardiovascular risk, and treatment goals.
